Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation

Cell Death and Disease

Volumn 5, Issue 5, 2014, Pages

  Perez Revuelta B I ^a   Hettich, M M ^a   Ciociaro, A ^a   Rotermund, C ^a   Kahle, P J ^a   Krauss, S ^a   Di Monte, D A ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Mice; MTOR; Parkinson; Phosphorylation; PP2A; Rapamycin

Indexed keywords

ALPHA SYNUCLEIN; ANTIBODY; BRAIN PROTEIN; DRINKING WATER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHOPROTEIN PHOSPHATASE 2A; RAPAMYCIN; SER 129 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; FOOD; HELA CELL LINE; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REDUCTION; WILD TYPE;

ALPHA-SYNUCLEIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; GESTATIONAL AGE; HELA CELLS; HIPPOCAMPUS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MICE, INBRED C57BL; NEURONS; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; SERINE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84901049587     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.175     Document Type: Article

References (43)

1. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzhemer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992; 8: 159-168.
2. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al. A-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-164.
3. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubuleassociated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997; 94: 298-303.
4. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goerdert M. a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-6473.
5. Anderson JP, Walker DE, Goldstein JM, de Laat R, Balducci K, Caccavello RJ et al. Phosphorylation of Ser-129 is the dominant pathological modification of a-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739-29752.
6. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of a-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010; 183: 115-145.
7. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T et al. Constitutive phosphorylation of the Parkinson's disease associated a-synuclein. J Biol Chem 2000; 275: 390-397.
8. Arawaka S, Wada M, Goto S, Karube H, Sakamoto M, Ren CH et al. The role of G-proteincoupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease. J Neurosci 2006; 26: 9227-9238.
9. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 2010; 285: 2807-2822.
10. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK et al. Enhanced phosphatase activity attenuates a-synucleinopathy in a mouse model. J Neurosci 2011; 31: 6963-6971.
11. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010; 107: 21830-21835.
12. Pahlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolesterinduced differentiation. Cell Differ 1984; 14: 135-144.
13. Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 2007; 365: 23-38.
14. Boudreau RT, Conrad DM, Hoskin DW. Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase. Cell Signal 2007; 19: 139-151.
15. Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem 2005; 280: 36029-36036.
16. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988; 256: 283-290.
17. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
18. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002; 277: 23977-23980.
19. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
20. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807-826.
21. Ha J, Daniel S, Broyles SS, Kim KH. Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994; 269: 22162-22168.
22. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012; 441: 1-21.
23. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D et al. LKB1 is the upstreamkinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
24. Tiainen M, Ylikorkala A, Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA 1999; 96: 9248-9251.
25. Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 2009; 27: e226.
26. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig 2011; 31: 435-438.
27. Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008; 23: 243-253.
28. Ahlin G, Hilgendorf C, Karlsson J, Szigyarto CA, Uhlen M, Artursson P. Endogenous gene and protein expression of drug-transporting proteins in cell lines routinely used in drug discovery programs. Drug Metab Dispos 2009; 37: 2275-2283.
29. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010; 176: 1169-1180.
30. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53: 569-596.
31. Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287-1295.
32. Liu E, Knutzen CA, Krauss S, Schweiger S, Chiang GG. Control of mTORC1 signaling by the Opitz syndrome protein MID1. Proc Natl Acad Sci USA 2011; 108: 8680-8685. 33.
33. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. Metformin, independent of AMPK, inhibitsmTORC1 in a rag GTPase-dependent manner. CellMetab 2010; 11: 390-401.
34. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71: 4366-4372.
35. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH et al. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet 2001; 29: 287-294.
36. Khandelwal PJ, Dumanis SB, Feng LR, Maguire-Zeiss K, Rebeck G, Lashuel HA et al. Parkinson-related parkin reduces a-synuclein phosphorylation in a gene transfer model. Mol Neurodegener 2010; 5: 47.
37. Febbrano F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D et al. Ser129D mutant a-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis 2013; 56: 47-58.
38. Braithwaite SP, Stock JB, Mouradian MM. a-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci 2012; 23: 191-198.
39. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006; 59: 449-458.
40. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of a-synuclein, tau and amyloid-b pathologies. Nat Rev Neurosci 2013; 14: 626-636.
41. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT et al. Initiation and synergistic fibrillization of tau and a-synuclein. Science 2003; 300: 636-640.
42. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B et al. Distinct a-synuclein strains differentially promote tau inclusions in neurons. Cell 2013; 154: 103-117.
43. Hasegawa T, Konno M, Baba T, Sugeno N, Kikuchi A, Kobayashi M et al. The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of a-synuclein. PLoS One 2011; 6: e29460.